Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release
Identifieur interne : 000404 ( Main/Corpus ); précédent : 000403; suivant : 000405Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release
Auteurs : O. RascolSource :
- European Journal of Neurology [ 1351-5101 ] ; 2011-03.
English descriptors
- KwdEn :
Abstract
Intermittent or pulsatile dopamine‐receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long‐term levodopa therapy of Parkinson’s disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine‐receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half‐lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini‐pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol‐O‐methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long‐term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once‐daily prolonged‐release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once‐daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.
Url:
DOI: 10.1111/j.1468-1331.2010.03326.x
Links to Exploration step
ISTEX:EB264198FD3D8898FDEC496F62F8DE6E31B30168Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation><mods:affiliation>Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EB264198FD3D8898FDEC496F62F8DE6E31B30168</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1468-1331.2010.03326.x</idno><idno type="url">https://api.istex.fr/document/EB264198FD3D8898FDEC496F62F8DE6E31B30168/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000404</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation><mods:affiliation>Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-03">2011-03</date><biblScope unit="volume">18</biblScope><biblScope unit="supplement">s1</biblScope><biblScope unit="page" from="3">3</biblScope><biblScope unit="page" to="10">10</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">EB264198FD3D8898FDEC496F62F8DE6E31B30168</idno><idno type="DOI">10.1111/j.1468-1331.2010.03326.x</idno><idno type="ArticleID">ENE3326</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>continuous dopaminergic stimulation</term><term>dopamine agonists</term><term>motor fluctuations</term><term>pramipexole extended‐release</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intermittent or pulsatile dopamine‐receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long‐term levodopa therapy of Parkinson’s disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine‐receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half‐lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini‐pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol‐O‐methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long‐term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once‐daily prolonged‐release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once‐daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>O. Rascol</name><affiliations><json:string>Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>continuous dopaminergic stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>motor fluctuations</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pramipexole extended‐release</value></json:item></subject><articleId><json:string>ENE3326</json:string></articleId><language><json:string>eng</json:string></language><abstract>Intermittent or pulsatile dopamine‐receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long‐term levodopa therapy of Parkinson’s disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine‐receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half‐lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini‐pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol‐O‐methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long‐term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once‐daily prolonged‐release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once‐daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.</abstract><qualityIndicators><score>7.024</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1716</abstractCharCount><pdfWordCount>4360</pdfWordCount><pdfCharCount>29251</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>222</abstractWordCount></qualityIndicators><title>Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title><genre><json:string>review-article</json:string></genre><host><volume>18</volume><publisherId><json:string>ENE</json:string></publisherId><pages><total>8</total><last>10</last><first>3</first></pages><issn><json:string>1351-5101</json:string></issn><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-1331</json:string></eissn><title>European Journal of Neurology</title><doi><json:string>10.1111/(ISSN)1468-1331</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1111/j.1468-1331.2010.03326.x</json:string></doi><id>EB264198FD3D8898FDEC496F62F8DE6E31B30168</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/EB264198FD3D8898FDEC496F62F8DE6E31B30168/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/EB264198FD3D8898FDEC496F62F8DE6E31B30168/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/EB264198FD3D8898FDEC496F62F8DE6E31B30168/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title><author><persName><forename type="first">O.</forename><surname>Rascol</surname></persName><affiliation>Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France</affiliation></author></analytic><monogr><title level="j">European Journal of Neurology</title><idno type="pISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><idno type="DOI">10.1111/(ISSN)1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-03"></date><biblScope unit="volume">18</biblScope><biblScope unit="supplement">s1</biblScope><biblScope unit="page" from="3">3</biblScope><biblScope unit="page" to="10">10</biblScope></imprint></monogr><idno type="istex">EB264198FD3D8898FDEC496F62F8DE6E31B30168</idno><idno type="DOI">10.1111/j.1468-1331.2010.03326.x</idno><idno type="ArticleID">ENE3326</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Intermittent or pulsatile dopamine‐receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long‐term levodopa therapy of Parkinson’s disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine‐receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half‐lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini‐pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol‐O‐methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long‐term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once‐daily prolonged‐release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once‐daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>continuous dopaminergic stimulation</term></item><item><term>dopamine agonists</term></item><item><term>motor fluctuations</term></item><item><term>Parkinson's disease</term></item><item><term>pramipexole extended‐release</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/EB264198FD3D8898FDEC496F62F8DE6E31B30168/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-1331</doi><issn type="print">1351-5101</issn><issn type="electronic">1468-1331</issn><idGroup><id type="product" value="ENE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="EUROPEAN JOURNAL OF NEUROLOGY">European Journal of Neurology</title></titleGroup></publicationMeta><publicationMeta level="part" position="03001"><doi origin="wiley">10.1111/ene.2011.18.issue-s1</doi><titleGroup><title type="specialIssueTitle">The Management of Parkinson’s Disease – What is New?</title></titleGroup><numberingGroup><numbering type="journalVolume" number="18">18</numbering><numbering type="supplement">s1</numbering></numberingGroup><coverDate startDate="2011-03">March 2011</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="2" status="forIssue"><doi origin="wiley">10.1111/j.1468-1331.2010.03326.x</doi><idGroup><id type="unit" value="ENE3326"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="tocHeading1">Review Articles</title></titleGroup><copyright>© 2011 The Author(s). European Journal of Neurology © 2011 EFNS</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.4.4 mode:FullText" date="2011-01-24"></event><event type="firstOnline" date="2011-01-24"></event><event type="publishedOnlineFinalForm" date="2011-01-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-17"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="3">3</numbering><numbering type="pageLast" number="10">10</numbering></numberingGroup><correspondenceTo>Olivier Rascol, MD, PhD, Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France (tel.: +33 561 14 59 62; fax: +33 561 14 56 42; e‐mail: <email>rascol@cict.fr</email>).</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ENE.ENE3326.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received 30 November 2010 Accepted 22 December 2010</unparsedEditorialHistory><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="1"></count></countGroup><titleGroup><title type="main">Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title><title type="shortAuthors">O. Rascol</title><title type="short">Drugs and drug delivery in PD: pramipexole prolonged‐release</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1"><personName><givenNames>O.</givenNames><familyName>Rascol</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="FR"><unparsedAffiliation>Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">continuous dopaminergic stimulation</keyword><keyword xml:id="k2">dopamine agonists</keyword><keyword xml:id="k3">motor fluctuations</keyword><keyword xml:id="k4">Parkinson's disease</keyword><keyword xml:id="k5">pramipexole extended‐release</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Intermittent or pulsatile dopamine‐receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long‐term levodopa therapy of Parkinson’s disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine‐receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half‐lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini‐pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol‐<i>O‐</i>methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long‐term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once‐daily prolonged‐release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once‐daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title></titleInfo><titleInfo type="abbreviated"><title>Drugs and drug delivery in PD: pramipexole prolonged‐release</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release</title></titleInfo><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Rascol</namePart><affiliation>Department of Clinical Pharmacology and Neurosciences, INSERM U825 and Clinical Investigation Center, University Hospital, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2011-03</dateIssued><edition>Received 30 November 2010 Accepted 22 December 2010</edition><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="tables">1</extent></physicalDescription><abstract lang="en">Intermittent or pulsatile dopamine‐receptor stimulation is postulated to induce plastic changes in motor systems that are responsible for the development of motor fluctuations and dyskinesia, complicating long‐term levodopa therapy of Parkinson’s disease (PD). Continuous dopamine stimulation (CDS) is a concept that refers to the hypothesis that more continuous dopamine‐receptor stimulation will reduce the risk of motor complications, particularly dyskinesias, and may also treat established dyskinesias. In line with this hypothesis, the intermittent administration of dopaminergic agents with short half‐lives induce motor complications in animal models, whilst the continuous administration of the same compounds via mini‐pumps substantially reduces such symptoms. Continuous drug delivery (CDD) strategies are therefore explored in clinical trials to prevent or manage motor complications. The early use of a dopamine agonist reduces the risk of motor fluctuations compared with levodopa. Conversely, the early combination of the catechol‐O‐methyltransferase inhibitor entacapone with levodopa has failed to demonstrate a comparable advantage. Outcomes of uncontrolled long‐term studies of PD patients with motor complications treated for several months with subcutaneous continuous infusion of apomorphine or intraduodenal levodopa are compatible with CDS. New once‐daily prolonged‐release formulations of dopamine agonists have demonstrated antiparkinsonian efficacy in randomized trials conducted in early as well as advanced patients with PD. Once‐daily administration is convenient and may improve compliance. Other theoretical advantages in terms of efficacy or tolerability deserve further exploration.</abstract><subject lang="en"><genre>Keywords</genre><topic>continuous dopaminergic stimulation</topic><topic>dopamine agonists</topic><topic>motor fluctuations</topic><topic>Parkinson's disease</topic><topic>pramipexole extended‐release</topic></subject><relatedItem type="host"><titleInfo><title>European Journal of Neurology</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1351-5101</identifier><identifier type="eISSN">1468-1331</identifier><identifier type="DOI">10.1111/(ISSN)1468-1331</identifier><identifier type="PublisherID">ENE</identifier><part><date>2011</date><detail type="title"><title>The Management of Parkinson’s Disease – What is New?</title></detail><detail type="volume"><caption>vol.</caption><number>18</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s1</number></detail><extent unit="pages"><start>3</start><end>10</end><total>8</total></extent></part></relatedItem><identifier type="istex">EB264198FD3D8898FDEC496F62F8DE6E31B30168</identifier><identifier type="DOI">10.1111/j.1468-1331.2010.03326.x</identifier><identifier type="ArticleID">ENE3326</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2011 The Author(s). European Journal of Neurology © 2011 EFNS</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000404 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000404 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:EB264198FD3D8898FDEC496F62F8DE6E31B30168
|texte= Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release
}}
| This area was generated with Dilib version V0.6.23. |  |